StockData
Nuo Therapeutics, Inc. logo

Nuo Therapeutics, Inc. (AURX) stock

AURXOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 8/30
$1.26−0.04 (-3.08%)

Close on Oct 19, 2026Market cap $60.99MP/E –Yield –

Nuo Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Nuo Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$2.45M. For fiscal 2025 it was -$1.14M. The highest annual figure on record is -$53.82K in fiscal 2020.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$1.14M–
FY2024Dec 31, 2024-$2.39M–
FY2023Dec 31, 2023-$3.18M–
FY2022Dec 31, 2022-$3.77M–
FY2021Dec 31, 2021-$119.96K–
FY2020Dec 31, 2020-$53.82K–
FY2019Dec 31, 2019-$921.67K–
FY2015Dec 31, 2015-$15.09M–
FY2014Dec 31, 2014-$17.91M–
FY2013Dec 31, 2013-$12.15M–
FY2011Dec 31, 2011-$4.31M–
FY2010Dec 31, 2010-$4.31M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$489.50K-287.8%
Q1 FY2026Mar 31, 2026-$785.12K–
Q4 FY2025Dec 31, 2025-$465.85K–
Q3 FY2025Sep 30, 2025-$706.52K–
Q2 FY2025Jun 30, 2025$260.70K–
Q1 FY2025Mar 31, 2025-$228.06K–
Q4 FY2024Dec 31, 2024-$490.54K–
Q3 FY2024Sep 30, 2024-$638.33K–
Q2 FY2024Jun 30, 2024-$695.27K–
Q1 FY2024Mar 31, 2024-$562.45K–
Q4 FY2023Dec 31, 2023-$671.41K–
Q3 FY2023Sep 30, 2023-$796.78K–
Q2 FY2023Jun 30, 2023-$905.89K–
Q1 FY2023Mar 31, 2023-$800.95K–
Q4 FY2022Dec 31, 2022-$826.34K–
Q3 FY2022Sep 30, 2022-$1.01M–
Q2 FY2022Jun 30, 2022-$1.18M–
Q1 FY2022Mar 31, 2022-$749.18K–
Q4 FY2021Dec 31, 2021-$106.95K–
Q3 FY2021Sep 30, 2021-$3.16K–
Q2 FY2021Jun 30, 2021-$5.68K–
Q1 FY2021Mar 31, 2021-$4.17K–
Q4 FY2020Dec 31, 2020-$33.57K–

More Nuo Therapeutics figures

See a number that looks wrong?